migraine
Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine
October 15, 2019Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma
Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
Lundbeck acquires Alder in $2bn migraine treatment move
September 16, 2019Sales and Marketing Alder, Lundbeck, eptinezumab, migraine
Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition …
4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine
September 9, 2019Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma
Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
Pfizer recall two batches of migraine drug Relpax
August 16, 2019Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall
Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …
Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population
August 6, 2019Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma
New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …
Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial
July 11, 2019Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma
Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …
Eli Lilly’s Emgality approved in the US for episodic cluster headache
June 5, 2019Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma
Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …
FDA approves Theranica’s smartphone-controlled electroceutical device for migraine
May 29, 2019Research and Development FDA, Nerivio Migra, Theranica, migraine, pharma
Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …
Top Ten most popular articles on Pharmafile.com this week!
May 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma
This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
May 8, 2019Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …
Teva’s Ajovy injection secures EU approval for the prevention of migraine
April 2, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma
Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …
NICE rejects Novartis’ Aimovig migraine injection for NHS use
January 10, 2019Sales and Marketing Aimovig, NICE, Novartis, migraine, pharma
It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS …
Eli Lilly’s Emgality cleared for treatment of migraine in Europe
November 20, 2018Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma
Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …
FDA greenlights Teva’s migraine drug Ajovy in two dosage options
September 20, 2018Sales and Marketing FDA, Teva, US, ajovy, migraine, pharma
Israeli drugmaker Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (remanezumab-vfrm) has received FDA approval as a …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
